Sunday, September 27, 2020
wellness India Expo
Home Tags R&D

Tag: R&D

Jubilant launches JUBI-R, its generic version of COVID-19 drug remdesivir in...

Jubilant Generics, a subsidiary of Jubilant Life Sciences has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection)........................

JNCASR spinoff launches molecular probes for use in COVID-19 test kits

The company has launched indigenous fluorescence probes and Polymerase chain reaction (PCR) mix for Reverse transcription-polymerase chain reaction (RT-PCR) detection which are molecular probes used in COVID-19 test kits.................

MTaI urges govt to release stalled imports of medical devices

Many consignments of essential medical devices imported by these companies are held up at various Indian ports since 22nd June 2020...............

DBT to establish 4 COVID-19 Bio Banks for facilitating research &...

The four Bio Repositories under the purview of the Department of Biotechnology (DBT) are NCR-Biotech Science Cluster including THSTI, Faridabad – Clinical samples and RCB Faridabad –Viral samples; Institute of Life Sciences, Bhubaneswar;  InStem, Bangalore;  and ILBS, New Delhi....................

COVID-19: Dr Harsh Vardhan calls it a war like situation, exhorts...

These are times of war, deliver solutions before the war ends, not a routine research project, stated the union science and technology minister, Dr Harsh Vardhan during his video interaction with directors of various CSIR institutes.....................

“We aim to bring newer drug innovations to the Indian market”

Mentioned Luca Visini, Managing Director, Eli Lilly & Company India in an exclusive interaction with BioVoice where he outlined the goals of his company driven by innovation including pursual of new drug development and working towards medicines reaching people at large through different channels.....................

Abbott launches modernized lab information system to boost R&D, manufacturing sectors

STARLIMS QM 12.0 is designed for the global manufacturing and R&D sectors including pharmaceuticals/biotech, chemicals and petrochemicals, oil and gas, food and beverage, contract services, consumer products and general manufacturing................

Special Startup Series: The quest for safer cancer cure

Pune based biotech startup, CyCa Oncosolutions is working on an indigenous drug delivery system that could target only cancer cells without any damage to adjoining tissues, eradicating the painful side effects and thus improving the quality of life of cancer patients.............

Record 59 new US drugs launched in 2018, success rates fall:...

As per the study by IQVIA Institute for Human Data Science, while the likelihood that a drug entering clinical development would be a success was 11 percent, down from 14 percent in 2017, eight identified trends could increase R&D productivity by double digits during next five years.................

“Agilent will continue to develop need based innovative technologies”

In an exclusive face to face interaction with the Bio Voice's Rahul Koul, the Country Manager of Agilent Technologies India, Mr Bharat Bhardwaj shared the details about the company's life sciences initiatives, latest product launches and future plans..............